HPV Vaccine for Adults Over 26: Is It Worth It?

For years, the HPV vaccine was framed as a pediatric vaccine — given to 11- and 12-year-olds before they were sexually active, with diminishing returns into the early 20s. That changed in 2018, when the FDA expanded approval of Gardasil 9 up to age 45. Suddenly, "should I get the HPV vaccine as an adult?" became a real question with a non-obvious answer.

Here is the current evidence-based take.

The short answer

If you are between 27 and 45 and have not been fully vaccinated against HPV:

  • The vaccine is FDA-approved and safe for you.
  • The benefit is smaller than for adolescents, because you have likely been exposed to some HPV strains already.
  • The benefit is not zero — Gardasil 9 covers nine HPV types, and most adults have not been exposed to all nine.
  • The CDC recommends shared decision-making with your doctor, meaning: it is reasonable, often worthwhile, but case-dependent.

For most adults under 45 who have not been vaccinated, the answer is closer to "yes, get it" than to "skip it." Insurance often covers it through age 45, even when out-of-pocket cost would be a barrier.

Why pediatric vaccination beats adult vaccination

HPV vaccines do two things:

  1. Prevent infection in people who have not yet been exposed.
  2. Have no therapeutic effect on existing infections — the vaccine cannot clear HPV you already have.

Adolescents typically have not been exposed to HPV yet. The vaccine prevents nearly 100% of infections from the nine strains it covers in this population.

By your late 20s and 30s, most sexually active people have been exposed to at least some HPV strains. The vaccine cannot help with those existing infections. It can only protect against the strains you have not yet been exposed to.

The trade-off shifts as you age, but it does not vanish.

How much benefit do adults actually get?

The pivotal Gardasil 9 trial for adults aged 27-45 (the data that supported the 2018 FDA expansion) found:

  • 88% reduction in persistent infection and disease caused by Gardasil 9 strains in the per-protocol analysis (adults who completed the three-dose series and were HPV-naive at baseline for the vaccine strains).
  • Benefit declines as more strains in your history overlap with the vaccine's coverage — i.e., the more HPV you have already been exposed to, the less the vaccine has to do.
  • No safety signals — adverse event rates were similar to the placebo arm.

The benefit is genuine but smaller in absolute terms than for adolescents. The CDC's "shared decision-making" language reflects this: not "everyone should get it," not "nobody should get it," but "consider your situation."

Who benefits most as an adult

The strongest case for adult HPV vaccination:

  • You have a new sexual partner or are dating after a long monogamous relationship. Each new partner is a new HPV exposure window.
  • You have had few sexual partners. Lower lifetime exposure means more vaccine strains you have not encountered yet.
  • You have men-who-have-sex-with-men (MSM) status, immunocompromised status, or HIV. Higher rates of anal HPV and anal cancer make the vaccine more impactful.
  • You are about to become sexually active for the first time.
  • You have a partner who has HPV. Vaccinating yourself does not clear their infection, but it can protect you from acquiring strains you have not been exposed to.

Who benefits less

The weaker case for adult HPV vaccination:

  • You are in a long-term monogamous relationship with a partner you have been with for many years. Most HPV transmission would have happened by now.
  • You have already had a documented HPV diagnosis (positive Pap, genital warts, cervical lesion biopsy). The vaccine cannot clear existing infection — though it may still protect against other vaccine-covered strains.
  • You are over 45. Off-label use is possible but no longer FDA-approved.

The three-dose schedule for adults

For adults aged 15-45 who start the series, the standard schedule is:

  • Dose 1: day zero
  • Dose 2: 1-2 months after dose 1
  • Dose 3: 6 months after dose 1

Pediatric schedules sometimes use only two doses, but for adults, three doses are standard because the immune response to two doses is weaker in older recipients.

What about single-dose Gardasil?

Recent World Health Organization-supported research suggests a single dose of Gardasil may be nearly as effective as the standard multi-dose schedule in girls and young women. Single-dose protocols are being rolled out in low- and middle-income countries as a way to scale coverage.

The WHO-backed single-dose evidence is mostly from adolescents. Whether single-dose protection holds in adults aged 27-45 has not been studied. For now, if you are an adult getting Gardasil 9 in the U.S., expect the standard 3-dose course.

Cost and access

  • Insurance coverage: Most U.S. health insurance plans cover Gardasil 9 through age 26 with no cost-sharing under ACA preventive-care rules. For ages 27-45, coverage is variable — many plans cover it with a copay, some don't cover it at all.
  • Out of pocket: Roughly $250 per dose, so ~$750 for the full three-dose course.
  • Patient assistance: Merck (Gardasil's manufacturer) runs a patient-assistance program for uninsured or underinsured adults. Your provider's office can help apply.
  • Local health departments and university health centers sometimes have lower-cost programs.

What the vaccine does not do

  • It does not clear existing HPV infections.
  • It does not treat genital warts you already have.
  • It does not eliminate the need for cervical cancer screening (Pap and HPV testing) — those continue as recommended by age and risk.
  • It does not protect against other STIs.
  • It is not 100% effective even against the strains it covers — about 90% of HPV-associated cancers come from vaccine-covered strains, but post-vaccination breakthrough is rare but possible.

What about people who got Gardasil (4-valent) years ago?

If you received the original Gardasil (which covered 4 HPV strains) in your teens, you have base protection. Gardasil 9 covers 9 strains — 5 additional ones. The CDC does not currently recommend routine revaccination of people already fully vaccinated with the 4-strain version, but it is permissible and is sometimes done for people at higher exposure risk.

If you only received 1-2 doses of any HPV vaccine in your youth and never completed the series, you should complete it now — even if you are over 26.

The bottom line

The HPV vaccine is FDA-approved for adults up to 45 and is safe and effective in this group. Benefit is smaller than for adolescents because of prior exposure, but it is real, especially if you have a new sexual partner, have had relatively few partners, or are in a higher-risk group (MSM, immunocompromised, HIV).

The CDC recommends shared decision-making rather than blanket vaccination for 27-45-year-olds. If you are in that window and have not been vaccinated, talking to your primary care provider about Gardasil 9 is worth a half hour. Most insurance plans cover at least part of the cost. The downside is small (mild injection site reaction). The upside is reduced risk of cervical, anal, throat, and other HPV-associated cancers years from now.

For everything on HPV — vaccine schedule, testing, persistent infections, cancer risks, and trials of therapeutic vaccines — see our complete HPV pillar guide.